Skip to main content

Table 1 Demographic characteristic for COPD patients with and without GORD

From: Gastro-oesophageal reflux disease increases the risk of intensive care unit admittance and mechanical ventilation use among patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study

Characteristic

With GORD ( n = 1,210)

Without GORD ( n = 2,420)

P value

Male

807 (66.69)

1,621 (66.98)

0.861a

Age

63.4 (±12.16)

63 (±12.38)

0.414a

Age category

   

 40 to 50

214 (17.69)

461 (19.05)

0.795a

 51 to 60

267 (22.07)

516 (21.32)

 

 61 to 70

309 (25.54)

632 (26.12)

 

 71 to 80

324 (26.78)

616 (25.45)

 

  ≥ 80

96 (7.93)

195 (8.06)

 

CCI category

   

 0

22 (1.82)

55 (2.27)

0.757a

 1 to 3

563 (46.53)

1,142 (47.19)

 

 4 to 6

415 (34.3)

802 (33.14)

 

  ≥ 7

210 (34.3)

421 (17.4)

 

Proxy COPD severity

40 (3.31)

79 (3.26)

0.947a

COPD medication

   

 SABA

171 (14.13)

396 (16.36)

0.081

 LABA

12 (0.99)

22 (0.91)

0.808

 SAMA

157 (12.98)

344 (14.21)

0.307

 Theophylline

1,071 (88.51)

2,066 (85.37)

0.009

 ICS

42 (3.43)

65 (2.67)

0.187

 LAMA

15 (1.24)

26 (1.07)

0.657

Vaccines

   

 Influenza and pneumococcal

454 (37.52)

890 (36.78)

0.662

Residential area

   

 Urban

675 (55.79)

1,363 (56.32)

0.888a

 Suburban

418 (34.55)

817 (33.76)

 

 Rural

117 (9.67)

240 (9.92)

 

Occupation category

   

 1

325 (26.86)

714 (29.5)

0.098a

 2

535 (44.21)

1,078 (44.55)

 

 3

350 (28.93)

628 (25.95)

 

Monthly insurance premium ($NT)b

   

 No fee

274 (22.64)

628 (25.95)

0.079a

 1 to 19,199

332 (27.44)

602 (24.88)

 

 19,200 to 23,999

400 (33.06)

817 (33.76)

 

  ≥ 24,000

204 (16.86)

373 (15.41)

 
  1. Data presented as n (%) or mean (± standard deviation). CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reflux disease; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; NT, new Taiwan dollar; SABA, short-acting β2-agonists; SAMA, short-acting muscarinic antagonists. aStandard difference. bUS$1 ≒ $NT30.